BIT's 10th Annual World DNA and Genome Day (WDD-2019)
★ Submission Guideline

1. The organizers of WDD-2019 welcome all abstracts within the scope of the meeting. Submitted abstracts will be reviewed by experts and be scheduled for either oral or poster presentation during the congress if the topic is relevant and the quality of the data justifies scheduling. Irrelevant or poor-quality abstracts may be rejected.

2. An Abstracts can be submitted online through the congress website. It is advisable to prepare the complete text of your abstract as well as any figures/tables before accessing online abstract submission.

3. Abstracts need to written in clear English, taking into account the specifications below.
a.    Maximum word count of abstract title: 20 words.
b.    Maximum word count of abstract text: 350 words (adjust in case of tables/figures).
c.    Abstract topic should be selected during the online submission process from the list of predefined topics to facilitate abstract review and scheduling.
d.    A minimum of three specific keywords should be added during online submission for indexing of the abstract. Specific keywords are: name(s) of drug(s) investigated, molecular target molecule(s), disease(s) studied, biochemical or biological function(s) studied. Avoid the use of vague keywords, such as: angiogenesis, cell death, cancer, tumor, drug development, drug therapy. The Organizing Committee of WDD-2019 reserves the rights to delete, edit, or add keywords to achieve uniformity throughout abstract publications.
e.    Use International Nonproprietary Names (INN) or research codes to identify drugs throughout the abstract. Proprietary names may be used in the abstract text, not the abstract title. The first time the drug is mentioned use the INN and put proprietary names between brackets.
f.    The identity of a new, previously unpublished drug substance should be disclosed in the abstract, either by providing its structural formula or its full chemical name

4. Abstracts will be published exactly as submitted. No editing of abstract texts will be done. However, non-adherence to the above guidelines may be corrected (e.g. use of drug names, keywords) by the meeting organizers.

5. After submission, abstracts can no longer be changed by the authors. Should minor changes be necessary after submission, the author should notify olivia at Jessica@dnaday.com, describing exactly the nature of the change to be made. The WDD-2019 organizers will then implement the change. If major changes are required the author should submit a revised abstract as an entirely new abstract and send a request to Jessica@dnaday.com. to delete the original abstract. The addition of a co-author constitutes a major change.

6. After completion of the abstract review, the submitting author will receive scheduling information via email. Abstracts cannot be withdrawn after receipt of the scheduling information by the submitting author. The presenting author must be registered as a participant of WDD-2019 for final scheduling and publication of the abstract.

7. Accepted abstracts will be published in the Conference Proceedings. The authors of the submitted abstracts are responsible for any Intellectual Property issues concerning the abstracts on their own. The organizing committee of WDD-2019 reserves the right to use submitted abstracts for conference purposes.

Honorary Chairman

Professor Pingkai Ouyang, Academician, The Chinese Academy of Engineering, China

Concurrent Conference
News Released
Speaking proposals are now being accepted
Call for Exhibitors and Sponsors
Call for Collaborative Partners, Media and Journals
Hosting Organizations

Information Research Center of International Talent, Ministry of Science and Technology, China

Jiangsu Pharmaceutical Association
Academic Supporting Organizations

Jiangsu Pharmaceutical Association Pharmacogenomic Professional Committee

Jiangsu Pharmaceutical Association Medical Biotechnology Professional Committee

Jiangsu Pharmaceutical Association Medicinal Chemistry Professional Committee
Operating Organizations

Zhen-Ao Group Co., Ltd.

SHUANGDI, INC.

BIT Congress Inc.

 

Official Travel Agency
Supporting Organization


European Medical Association

BIT’s Upcoming Events
About conference Participant Media
Welcome Message
Program Committee
Hotel & Venue
Visa
Help & FAQs
Participant Guideline
Submission Guideline
Media Partners
Media Partner List
Registration Program Sponsorship & Exhibition
Registration Instruction
Price & Payment
Registration
Cancellation
Deadline
Schedule
Program
Social Event
Sponsorship Opportunity
Exhibition
Poster

Add: East Area, F11, Building 1, Dalian Ascendas IT Park, 1 Hui Xian Yuan, Dalian Hi-tech Industrial Zone, LN 116025, China
Tel: 0086-411-84799609 Fax: 0086-411-84799629 Email: francis@bitlifesciences.com
Copyright © 2004-2019. BIT Congress Inc.